Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by conspiTheoryon Sep 14, 2013 2:04pm
377 Views
Post# 21740655

just a buyback at the friendly fair market price.

just a buyback at the friendly fair market price.
shorts
2013-08-31 1,225,348 402,848 105,890,404 1.16%
2013-08-15 822,500 822,500 105,890,404 0.78%


So Urocidin will be approved only in which country first? Will Urocidin be part of that special club?

Approval Times

Of 584 new therapeutic drugs approved in the 20- year period that satisfied the study definition, 554 (94.7%) were approved in the US and 484 (82.9%) in Canada; 454 (77.7%) were approved in both countries. In each country, the median review time for the country-specific drugs was generally longer than that for the drugs approved in both countries (Appendices A and B), but the only difference that was marginally statistically significant was in priority status drugs in Canada. Nevertheless, the drugs approved in Canada alone constituted just 6.2% of all drugs approved in the country and only varied between 2.1% and 11.0% across the four approval periods, whereas in the US, the corresponding rate was 18.1%, which increased sharply from 8.0% to 36.8% across the four periods.

Of the 454 drugs, 385 (84.8%) were submitted and 386 (85.0%) approved first in the US.

https://www.ncbi.nlm.nih.gov/pubmed/23650206

<< Previous
Bullboard Posts
Next >>